Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: A trial on pigs

Journal of Controlled Release

Volumn 145, Issue 3, 2010, Pages 214-220

  Campisi, Giuseppina ^a   Giannola, Libero Italo ^a   Florena, Ada Maria ^a   De Caro, Viviana ^a   Schumacher, Axel ^b   Göttsche, Thorsten ^b   Paderni, Carlo ^a   Wolff, Andy ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b Institute of Micromachining and Information Technology   (Germany)

^c ASSUTA MEDICAL CENTER   (Israel)

Author keywords

IntelliDrug intraoral device; Iontophoresis; Naltrexone hydrochloride; Porcine buccal mucosa; Transmucosal delivery

Indexed keywords

ADVERSE SIDE EFFECTS; BLOOD LEVELS; BLOOD SAMPLES; BUCCAL MUCOSA; CROSS-OVER; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; ELECTRONIC DEVICE; HISTOLOGICAL ANALYSIS; HISTOMORPHOLOGICAL CHANGES; IN-VIVO; LC/MS/MS; LONG LASTING; NALTREXONE; OPIATE ADDICTION; PATIENT COMPLIANCE; PERMEATION ENHANCEMENT; PLASMA LEVELS; SHARP INCREASE; TISSUE DAMAGE;

BIOCHEMISTRY; BLOOD; CUSTOMER SATISFACTION; DRUG DOSAGE; DRUG PRODUCTS; ELECTRON DEVICES; ELECTROPHORESIS; ELECTROTHERAPEUTICS;

CONTROLLED DRUG DELIVERY;

NALTREXONE; NARCOTIC ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEEK MUCOSA; CONTROLLED STUDY; DEVICE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ELECTRONICS; FEMALE; IN VIVO STUDY; INTRAORAL ELECTRONIC DEVICE; IONTOPHORESIS; NONHUMAN; PRIORITY JOURNAL; SWINE; TISSUE INJURY; ANIMAL; BIOAVAILABILITY; BLOOD; BUCCAL DRUG ADMINISTRATION; DEVICES; EQUIPMENT DESIGN; EVALUATION STUDY;

ADMINISTRATION, BUCCAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; NALTREXONE; NARCOTIC ANTAGONISTS; SWINE;

EID: 77954310097     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.04.027     Document Type: Article

References (16)

1. Yin W., Akala E.O., Taylor R.E. Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles. Int. J. Pharm. 2002, 244:9-19.
2. Myrick H., Anton R. Recent advances in the pharmacotherapy of alcoholism. Curr. Psychiatry Rep. 2004, 6:332-338.
3. David S., Lancaster T., Stead L.F. Opioid antagonists for smoking cessation. Cochrane Database Syst. Rev. 2001, CD003086.
4. Verebey K., Volavka J., Mule S.J., Resnick R.B. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin. Pharmacol. Ther. 1976, 20:315-328.
5. Verebey K. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. NIDA Res. Monogr. 1981, 28:147-158.
6. Valiveti S., Paudel K.S., Hammell D.C., Hamad M.O., Chen J., Crooks P.A., Stinchcomb A.L. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs. Pharm. Res. 2005, 22:981-989.
7. Bouza C., Angeles M., Munoz A., Amate J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004, 99:811-828.
8. Leri F., Burns L.H. Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol. Biochem. Behav. 2005, 82:252-262.
9. Comer S.D., Collins E.D., Kleber H.D., Nuwayser E.S., Kerrigan J.H., Fischman M.W. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 2002, 159:351-360.
10. Johnson B.A. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem. Pharmacol. 2008, 75:34-56.
11. Johnson B.A. Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther. Clin. Risk Manag. 2007, 3:741-749.
12. Johnson B.A. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opin. Pharmacother. 2006, 7:1065-1073.
13. Giannola L.I., De Caro V., Giandalia G., Siragusa M.G., Tripodo C., Florena A.M., Campisi G. Release of naltrexone on buccal mucosa: permeation studies, histological aspects and matrix system design. Eur. J. Pharm. Biopharm. 2007, 67:425-433.
14. Giannola L.I., De Caro V., Giandalia G., Siragusa M.G., Campisi G., Florena A.M., Ciach T. Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features. Eur. J. Pharm. Biopharm. 2007, 65:238-246.
15. Scholz O.A., Wolff A., Schumacher A., Giannola L.I., Campisi G., Ciach T., Velten T. Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov. Today 2008, 13:247-253.
16. Dash A.K., Cudworth G.C. Therapeutic applications of implantable drug delivery systems. J. Pharmacol. Toxicol. Methods 1998, 40:1-12.